Obinutuzumab May Be an Effective and Safe Option for Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis Patients after Multitarget Therapy Including Rituximab
2024 · American Journal of Nephrology · 9 citations
https://doi.org/10.1159/000541972